Reference Standards

OncoSpot™ NGS Spike-in Reference Standards

Genecopoeia provides OncoSpot™ NGS Spike-in Reference Standards for monitoring the whole process of the detection. The CRISPR method is employed to modify the genome of tumour cells, introducing single nucleotide mutations or in-frame indel mutations. Concurrently, spike-in markers are set up using our patented technology ‘DNA reference standard and use thereof’.
read more

OncoSpot™ NGS Reference Standards

GeneCopoeia's OncoSpot™ NGS Reference Standards use highly characterized HCT116 cell lines, genetically modified with advanced genome editing technology to include clinically relevant cancer gene mutations, just as they occur in patient tumors. The...
read more

OncoSpot™ NGS Spike-in Reference Standards

Genecopoeia provides OncoSpot™ NGS Spike-in Reference Standards for monitoring the whole process of the detection. The CRISPR method is employed to modify the genome of tumour cells, introducing single nucleotide mutations or in-frame indel mutations. Concurrently, spike-in markers are set up using our patented technology ‘DNA reference standard and use thereof’.

read more